Prospects for Implementing Continuous Flow Reactors for the Industrial Synthesis of APIs Based on Organometallic Reagents

Abstract

The modern pharmaceutical industry requires the implementation of highly efficient synthesis methods for active pharmaceutical ingredients (APIs) based on "green chemistry" and safety. Using highly reactive organometallic reagents like n-butyllithium in traditional batch processes poses risks of thermal runaway, necessitating extreme cooling (-78 °C) and high energy costs. Continuous flow reactors offer a solution to reduce technological hazards and increase efficiency for such dangerous industrial-scale syntheses